Ablevia is a research and development company that develops therapeutics for selective antibody removal. Its proprietary platform technology enables the development of compounds targeting undesired antibodies, autoantibodies, harmful antibodies in transplant rejection or anti-drug antibodies, neutralizing antibodies.